Results 201 to 210 of about 4,101 (234)
Some of the next articles are maybe not open access.
Zulassung des ersten BTKI der 2. Generation
InFo Hämatologie + Onkologie, 2021exaly +2 more sources
Abstract 4679: Molecular pathology and BTKi pharmacology of DLBCL-PDXs
Cancer Research, 2023Abstract Diffuse large B-cell lymphoma (DLBCL), the largest subtype of non-Hodgkin’s lymphoma (NHL, ~40%), is a heterogeneous disease with diverse pathogenesis, represented by different subtypes/genotypes based on lymphoma related specific gene expression profiling according to cell-of-origin (COO) and/or mutation profiles, likely ...
Jingjing Wang +6 more
openaire +1 more source
Abstract 4725: The epigenetic determinants of BTKi efficacy in chronic lymphocytic leukemia
Cancer Research, 2023Abstract Introduction: The introduction of Bruton’s tyrosine kinase (BTK) inhibitors (BTKi) to target B cell receptor (BCR) pathways in chronic lymphocytic leukemia (CLL) has significantly improved clinical responses. However, the effectiveness of BTKi is limited by the development of adaptive drug resistance.
Zhiquan Wang +5 more
openaire +1 more source
Blood AdvancesClinical Lymphoma Myeloma and Leukemia, 2021
Abstract The advent of small molecule inhibitors of B-cell receptor (BCRi) signaling has revolutionized the therapy for patients with chronic lymphocytic leukemia (CLL). These therapies have largely supplanted cytotoxic chemotherapy for both untreated and relapsed disease.1,2 The Bruton’s tyrosine kinase (BTK) inhibitors, ibrutinib and acalabrutinib ...
openaire +1 more source
Abstract The advent of small molecule inhibitors of B-cell receptor (BCRi) signaling has revolutionized the therapy for patients with chronic lymphocytic leukemia (CLL). These therapies have largely supplanted cytotoxic chemotherapy for both untreated and relapsed disease.1,2 The Bruton’s tyrosine kinase (BTK) inhibitors, ibrutinib and acalabrutinib ...
openaire +1 more source
Relapsed/Refractory CLL/SLL: Overcoming Resistance to Covalent BTKi and/or BCL2 Inhibitors
Journal of the National Comprehensive Cancer Network, 2023We are now in the era of targeted therapy for frontline chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with current treatments demonstrating favorable long-term outcomes. However, patients with double-refractory CLL whose disease has relapsed or been refractory to treatment with both a BTK and BCL-2 inhibitor present a unique ...
openaire +1 more source
Hub Genes Identification in Btki Resistant Mantle Cell Lymphoma
Blood, 2022Shuozi Liu +4 more
openaire +1 more source
Polypharmazie - Wechselwirkungen der BTKi
Oncology Research and Treatment, 2022openaire +1 more source